Ozempic® vs Mounjaro — patent estate comparison

Side-by-side. 2 estates compared across 0 active patents and $0.0B combined annual revenue.

Drug
Ozempic®
Ozempic®
Mounjaro
Mounjaro
Originator
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Nicholas Skertich
Annual revenue
—
—
Active patents
0
0
Avg vulnerability
—
—
Ironclad (<25)
0
0
Vulnerable (≥70)
0
0
Earliest cliff
—
—
Latest expiry
—
—
Cliff (next 15y)

No expiries next 15y

No expiries next 15y

Top claim types
Strongest defences

—

—

Most vulnerable

—

—

Try other comparisons

keytruda vs opdivo vs tecentriqhumira vs enbrel vs remicadeozempic vs mounjaro vs wegovyimbruvica vs calquence vs brukinsa

Want AI commentary on this comparison? Run the AI Patent Landscape Report on the drug class.